Please login to the form below
US Department of Justice
This page shows the latest US Department of Justice news and features for those working in and with pharma, biotech and healthcare.
Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition
The proposed transaction would mark a significant boost to the US pharma’s oncology pipeline. ... The second request is a standard review procedure by which the FTC and the Antitrust Division of the US Department of Justice investigate mergers and
Latest news
-
US Supreme Court halts Purdue Pharma $6bn bankruptcy settlement
In a single-page order, the court granted the US Department of Justice's request to temporarily block the plan and said it would hold oral arguments in December. ... However, the US Department of Justice bankruptcy watchdog, the Office of the US Trustee,
-
US Supreme Court asked to block Purdue Pharma bankruptcy settlement
The number of opioid overdoses has increased in recent years, causing the US Department of Health and Human Services to renew its previously declared public health emergency in December 2022. ... However, the US Department of Justice bankruptcy watchdog,
-
US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition
The US Federal Trade Commission (FTC) has requested more information and documentary material regarding Pfizer’s proposed $43bn acquisition of Seagen. ... The second request is a standard review procedure by which the FTC and the Antitrust Division of
-
Biogen to pay $900m to settle whistleblower’s MS drug kickback lawsuit
The US Department of Justice explained in a statement that the settlement resolves a long-running lawsuit filed and litigated by former Biogen employee Michael Bawduniak, on behalf of the US ... Principal Deputy Assistant Attorney General Brian Boynton,
-
Teva reaches $925,000 settlement to resolve drug price-fixing claims
Last year, the US Department of Justice charged Teva for conspiring with competitors in a generic drug price-fixing probe. ... Then, last year, the US Department of Justice (DoJ) charged Teva for conspiring with competitors in a generic drug
More from news
Approximately 6 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
Will biosimilars ever catch on in the US?
As prices in the US continue to spiral out of control, we can only look on with envy. ... Department of Justice.
-
As the opioid crisis grabs the headlines, the search for safe treatments continues
Its share price took a massive hit when it was indicted by the US Justice Department earlier this year over its Suboxone Film therapy for opioid and heroin addiction, but its ... Pipeline provides hope. Indivior is fighting the Department of Justice
-
Cybersecurity
Generally the draft Regulation will not change this approach. One method of seeking to meet the adequacy requirement when transferring personal data to the US (which is not an approved country ... test). Following the decision in the Schrems case last
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
